Alignment Healthcare (ALHC) Stock Forecast & Price Target

Alignment Healthcare is positioned to benefit from a favorable Medicare Advantage backdrop as larger carriers optimize footprints and retreat from less attractive markets, creating room for share gains through its consumer-centric, tech-enabled model. Its proprietary AVA platform and Care Anywhere clinical network support better medical cost control, with 2Q26 adjusted MBR improving to 86.3%, adjusted EBITDA rising 48% to $68mm, and membership reaching about 294k, up 31% year over year. Management also estimates roughly $880mm of embedded gross profit potential in the existing base versus about $640mm at the midpoint of 2026 guidance, while expansion across California, Nevada, North Carolina, and Texas should deepen scale and operating leverage.

Alignment Healthcare is facing a deteriorating fundamental setup because its largest California HMO contract, representing about 75% of membership, fell from 4.0 to 3.5 stars, pushing much of the enrollment below the 4-star bonus threshold for payment year 2028 and creating meaningful uncertainty around future benefit economics. Near-term earnings visibility is also weak as management has cited persistent institutional acute care and SNF cost pressure, while the company is adding roughly $10mm-$11mm of second-half 2026 investments that could weigh on gross profit and make Q3 and Q4 results harder to underwrite. Although enrollment rose 23% to 226.7K in 2026 and California remains a strong growth market, the combination of unresolved CMS litigation, lower 2026/2027/2028 EBITDA estimates of $140m/$196m/$255m, and a possible $48 PMPM revenue headwind in 2028 supports a bearish outlook.